These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

723 related articles for article (PubMed ID: 33163697)

  • 1. The Impact of COVID-19 on Brachytherapy During the Pandemic: A Rutgers-Robert Wood Johnson Barnabas Health Multisite Experience.
    Hathout L; Ennis RD; Mattes MD; Wagman RT; Grann A; Jabbour SK; Singh R; Yue NJ; Haffty BG; Vergalasova I
    Adv Radiat Oncol; 2021; 6(1):100600. PubMed ID: 33163697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of the COVID-19 pandemic on brachytherapy and cancer patient outcomes: A systematic review.
    Parikh S; Zhang Y; Sherwani Z; Kumar R; Ohri N; Jan I; Vergalasova I; Jabbour S; Hathout L
    Brachytherapy; 2024; 23(2):141-148. PubMed ID: 38307787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A two-center experience: The impact of COVID-19 on two brachytherapy programs in Ontario - virtual care, service suspension and radiation therapy workflow.
    Chan K; Timotin E; Chung P; Han K; Milosevic M; Schnarr K; Sur R; Bosche J; Harnett N
    J Med Imaging Radiat Sci; 2023 Sep; 54(3):436-445. PubMed ID: 37357051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radical External-Beam Radiotherapy in Combination With Intracavitary Brachytherapy for Localized Carcinoma of the Cervix in Sri Lanka: Is Treatment Delayed Treatment Denied?
    Joseph N; Jayalath H; Balawardena J; Skandarajah T; Perera K; Gunasekera D; Weerasinghe S; Hoskin P; Choudhury A
    JCO Glob Oncol; 2020 Oct; 6():1574-1581. PubMed ID: 33079608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of the Coronavirus Disease of 2019 Pandemic on Radiation Oncology Clinical Decision Making in a High-Prevalence Environment.
    Pendyala P; Goglia AG; Mattes MD; Grann A; Huang D; Wagman RT; Yehia ZA; Yoon J; Ennis RD
    Adv Radiat Oncol; 2021; 6(3):100680. PubMed ID: 33686375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of a positive COVID-19 test on timeliness of radiation in patients receiving brachytherapy.
    Roach E; Hutten R; Johnson S; Suneja G; Tward J; Petereit D; Gaffney D
    Brachytherapy; 2024; 23(3):360-367. PubMed ID: 38395662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 impact on timing of brachytherapy treatment and strategies for risk mitigation.
    Williams VM; Kahn JM; Harkenrider MM; Chino J; Chen J; Fang LC; Dunn EF; Fields E; Mayadev JS; Rengan R; Petereit D; Dyer BA
    Brachytherapy; 2020; 19(4):401-411. PubMed ID: 32359937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes and toxicities in patients with intermediate-risk prostate cancer treated with brachytherapy alone or brachytherapy and supplemental external beam radiation therapy.
    Schlussel Markovic E; Buckstein M; Stone NN; Stock RG
    BJU Int; 2018 May; 121(5):774-780. PubMed ID: 29319919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
    Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does an Algorithmic Approach to Using Brachytherapy and External Beam Radiation Result in Good Function, Local Control Rates, and Low Morbidity in Patients With Extremity Soft Tissue Sarcoma?
    Klein J; Ghasem A; Huntley S; Donaldson N; Keisch M; Conway S
    Clin Orthop Relat Res; 2018 Mar; 476(3):634-644. PubMed ID: 29443850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Prospective Phase 2 Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Cancer After External Beam Radiation Therapy (NRG Oncology/RTOG-0526).
    Crook JM; Zhang P; Pisansky TM; Trabulsi EJ; Amin MB; Bice W; Morton G; Pervez N; Vigneault E; Catton C; Michalski J; Roach M; Beyer D; Jani A; Horwitz E; Donavanik V; Sandler H
    Int J Radiat Oncol Biol Phys; 2019 Feb; 103(2):335-343. PubMed ID: 30312717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. External beam radiation and brachytherapy boost at different facilities is associated with increased treatment delays in cervical cancer.
    Li R; Germino E; Horne ZD; Vargo JA; Chen YJ; Glaser S
    Int J Gynecol Cancer; 2020 Oct; 30(10):1505-1512. PubMed ID: 32928924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: the William Beaumont phase II dose-escalating trial.
    Martinez AA; Kestin LL; Stromberg JS; Gonzalez JA; Wallace M; Gustafson GS; Edmundson GK; Spencer W; Vicini FA
    Int J Radiat Oncol Biol Phys; 2000 May; 47(2):343-52. PubMed ID: 10802358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Five-year outcomes from a prospective comparative effectiveness study evaluating external-beam radiotherapy with or without low-dose-rate brachytherapy boost for localized prostate cancer.
    Pasalic D; Barocas DA; Huang LC; Zhao Z; Koyama T; Tang C; Conwill R; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup AM; Cooperberg MR; Hashibe M; O'Neil BB; Kaplan SH; Greenfield S; Penson DF; Hoffman KE
    Cancer; 2021 Jun; 127(11):1912-1925. PubMed ID: 33595853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term oncologic outcomes of low dose-rate brachytherapy compared to hypofractionated external beam radiotherapy for intermediate -risk prostate cancer.
    Sanmamed N; Joseph L; Crook J; Craig T; Warde P; Tomasso AD; Chung P; Berlin A; Bayley A; Saibishkumar EP; Glicksman R; Raman S; Catton C; Helou J
    Brachytherapy; 2023; 22(2):188-194. PubMed ID: 36549968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of brachytherapy on prostate cancer-specific mortality for definitive radiation therapy of high-grade prostate cancer: a population-based analysis.
    Shen X; Keith SW; Mishra MV; Dicker AP; Showalter TN
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1154-9. PubMed ID: 22270175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of external beam radiotherapy versus permanent seed brachytherapy as monotherapy for intermediate-risk prostate cancer - a single center Canadian experience.
    Delouya G; Lambert C; Bahary JP; Beauchemin MC; Barkati M; Ménard C; Taussky D
    Can J Urol; 2017 Jun; 24(3):8822-8826. PubMed ID: 28646937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.